Penny stocks are risky. That’s why we attach a warning to the tail-end of penny stock articles. It’s also why the SEC warns of their dangers.
In short, pay close attention to the warnings. Never risk more than you can afford to lose. Always have a protective stop loss in place.
And pay close attention to the penny stocks where insiders are putting their money where their mouth is. After all, it’s the insiders who know their company the best. If they’re buying a sizable number of shares, it’s often a good idea to start looking into why.
Here are three to consider. Monopar Therapeutics ( MNPR ) Monopar Therapeutics (NASDAQ: MNPR ) — a clinical-stage radiopharmaceutical — saw its chief operating officer buy about 36,000 shares. Helping, the company just initiated its Phase 1 dosimetry clinical trial for its novel radiopharmaceutical imaging agent MNPR-101-Zr.
According to the company, “The antibody MNPR-101 targets the urokinase plasminogen activator receptor, which is expressed on numerous tumor types including pancreatic, breast, colorectal, and bladder.” In addition, “Monopar recently shared positive preclinical efficacy data showing potent and durable anti-tumor activity of MNPR-101 bound to therapeutic radioisotopes.” Analysts at Jones Research recently upgraded MNPR to a Buy rating with a $2 price target.
Earnings haven’t been too shabby. In its most recent quarter, the company posted an EPS loss of 10 cents, beating estimates for a loss of 14 cents.
